Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia
Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new approach to obtain remission in malignancies by restoring the terminal maturation of leukemia cells re...
متن کاملDifferentiation Therapy of Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a predominant acute leukemia among adults, characterized by accumulation of malignantly transformed immature myeloid precursors. A very attractive way to treat myeloid leukemia, which is now called 'differentiation therapy', was proposed as in vitro studies have shown that a variety of agents stimulate differentiation of the cell lines isolated from leukemic pati...
متن کاملRetinoid differentiation therapy in promyelocytic leukemia.
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t(15;17) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all-trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARalpha...
متن کاملTherapy of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults1. Over the past twenty years, the studies on the pathogenesis and prognosis of AML have made considerable progress. Clinically, patients with AML typically present with signs or symptoms of bone marrow failure, although sometimes they can present with symptoms of leukostasis with pulmonary or neurological dysfuncti...
متن کاملPrecision therapy for acute myeloid leukemia
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease. Despite advances in understanding the pathogenesis of AML, the standard therapy remained nearly unchanged over the past three decades. With the poor survival for older patients and high relapse rate, multiple studies are ongoing to address this important issue. Novel therapies for AML, including the refinements ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia Research and Treatment
سال: 2012
ISSN: 2090-3219,2090-3227
DOI: 10.1155/2012/939021